According to the official website of the Drug Clinical Trial Registration and Information Public Platform, hybio pharmaceutical has initiated a Phase III clinical trial to compare the efficacy and safety of HY310 injection with novo-nordisk's treatment in obese patients for 44 weeks. The first public information of this trial was released on September 2. The drug name of HY310 injection is none other than the famous semaglutide. According to the Insight database, there are currently 27 domestic companies developing semaglutide analogues/improved new drugs, of which 13 are targeting the indication of obesity. The HY310 injection of hybio pharmaceutical mentioned above is the first domestic version of semaglutide to enter Phase III clinical trials for the indication of obesity. The original manufacturer of semaglutide is Novo Nordisk, a pharmaceutical company from Denmark, which generated over 3 billion USD in revenue in the first half of the year solely from the weight loss indication of this drug. Previously, CSPC Pharma and Jiuyuan Gene have also applied for the listing of semaglutide biosimilars, but the indication they applied for is type 2 diabetes, not weight loss. (Pengpai)